# DESCRIPTION

## TECHNICAL FIELD

- introduce immunostimulatory oligonucleotides

## BACKGROUND ART

- summarize immunostimulatory oligonucleotides
- limitations of current immunostimulatory oligonucleotides

## SUMMARY OF INVENTION

### Solution to Problem

- motivate non-aggregated A/D type ODN
- describe modification of D35
- summarize properties of modified D35
- claim advantages of modified D35

### Advantageous Effects of Invention

- summarize benefits of invention

## DESCRIPTION OF EMBODIMENTS

- define terms and concepts
- describe CpG oligonucleotides and their properties
- explain types of CpG ODNs and their characteristics
- discuss immunostimulatory activity of CpG ODNs
- describe modified CpG ODNs with phosphorothioate polynucleotide tails
- explain physical properties and solubility of modified CpG ODNs
- provide examples of oligonucleotides used in the invention
- define therapeutic agent
- define prevention and prophylactic agent
- describe kit and instruction
- describe medicament, dosage form, and administration route
- describe composition, carrier, and excipient
- describe salt, solvate, and chemical modification
- describe delivery system, administration method, and patient
- introduce immunostimulatory oligonucleotide nucleic acid medicine
- describe limitations of conventional techniques
- motivate phosphorothioated nucleotide for delivery
- describe structure and activity correlation of nucleic acid
- provide examples of agents for delivery
- describe biological activator focused on core sequence
- define oligonucleotide of invention
- describe embodiments of oligonucleotide
- provide agent for immunostimulation
- describe use of oligonucleotide
- outline general techniques

### EXAMPLES

- introduce experimental setup
- describe preparation of human PBMCs
- detail CpG ODN stimulation with or without DOTAP
- measure cytokines by ELISA
- perform dynamic light scattering and transmission electron microscopy
- conduct cynomolgus monkey immunization
- analyze statistical significance
- discuss results and implications
- conduct experiments for understanding requirements
- study direct solubility of immunostimulatory ODN in saline
- attempt to improve immunostimulatory profile by complex formulation
- examine in vivo adjuvant efficacy in monkey vaccine models
- discuss results and implications
- analyze cytokine reactions and adjuvanticity
- discuss differences in reactions among individuals
- confirm results with other CpG ODNs
- present experimental results
- demonstrate aggregation suppressing effect
- provide formulation examples

## INDUSTRIAL APPLICABILITY

- identify industries

